Biogen’s Alzheimer’s drug sales remain slow as company warns of further cost cuts
Biogen recorded $1 million in revenue from its new treatment for Alzheimer's disease in the last quarter of 2021, offering the latest evidence that the drug, which ca...
Continue Reading →
